Intercept Pharmaceuticals Inc (ICPT)
110.87
+3.39 +3.15%
NASDAQ
Dec 9, 20:00
Delayed 2m
USD
View All Key Stats
Key Stats
| Income Statement | |
| Revenue (TTM) | 233.78M |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (TTM) | -10.87 |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Net Income (TTM) | -334.53M |
| Profitability | |
| Gross Profit Margin (Quarterly) | 99.21% |
| Profit Margin (Quarterly) | -136.9% |
| Dividend | |
| Dividend Yield (Forward) | Upgrade |
| Dividend Yield (TTM) | 0.00% |
| Price and Valuation | |
| Market Cap | 3.629B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| PS Ratio (TTM) | 14.64 |
| PE Ratio (TTM) | -- |
| Price to Book Value | 27.76 |
| Other | |
| Beta (5Y) | Upgrade |
| Debt to Equity Ratio (Quarterly) | 4.018 |
| Free Cash Flow (Quarterly) | -46.77M |
| Return on Equity (TTM) | Upgrade |
View All ICPT News
News
-
WireHeadlineTime (ET)
-
MT Newswires12/06 05:13
-
Globe Newswire12/05 19:00
-
Yahoo12/05 11:31
-
Yahoo12/03 04:50
-
MT Newswires12/02 12:11
-
Yahoo12/02 09:04
-
SA Breaking News12/02 08:59
-
MT Newswires12/02 08:23
-
Globe Newswire12/02 08:00
-
Yahoo11/29 11:24
View All Events
Events
| Date | Type | Description |
|---|---|---|
| 02/28/2020 08:30 EST | Misc | Intercept Pharmaceuticals Inc Fourth Quarter Earnings Conference Call in 2019 |
| 02/28/2020 | Earnings | Intercept Pharmaceuticals Inc Fourth Quarter Earnings in 2019 Release |
| 11/05/2019 08:30 EST | Misc | Intercept Pharmaceuticals Inc Third Quarter Earnings Conference Call for 2019 |
| 11/05/2019 | Earnings | Intercept Pharmaceuticals Inc Third Quarter Earnings for 2019 Release |
| 08/07/2019 08:30 EDT | Misc | Intercept Pharmaceuticals Inc Second Quarter Earnings Conference Call in 2019 |
| 08/07/2019 | Earnings | Intercept Pharmaceuticals Inc Second Quarter Earnings in 2019 Release |
| 06/20/2019 10:00 EDT | Misc | Intercept Pharmaceuticals Inc Annual General Meeting in 2018 |
| 05/08/2019 08:30 EDT | Misc | Intercept Pharmaceuticals Inc First Quarter Earnings Conference Call in 2019 |
| 05/08/2019 | Earnings | Intercept Pharmaceuticals Inc First Quarter Earnings in 2019 Release |
| 03/01/2019 | Misc | Intercept Pharmaceuticals Inc Annual Report in 2018 |
Fundamentals
Income Statement View Statement
Ratings & Reports
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
- One Page Report Download
Advertisement
Edit
Profile
- URL: https://www.interceptpharma.com
- Investor Relations URL: http://ir.interceptpharma.com/index.cfm
- HQ State/Province: New York
- Sector: Healthcare
- Industry: Biotechnology
- Equity Style: Small Cap/Growth
- Next Earnings Release: Feb. 28, 2020
- Last Earnings Release: Nov. 05, 2019
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: N/A
- Description: Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH. Intercept owns worldwide rights to OCA outside of China, where it has licensed out the product to Sumitomo Dainippon Pharma.
Analyst Coverage
| Consensus Recommendations | |
| Buy Recommendations | Upgrade |
| Outperform Recommendations | Upgrade |
| Hold Recommendations | Upgrade |
| Underperform Recommendations | Upgrade |
| Sell Recommendations | Upgrade |
| Consensus Recommendation | Upgrade |
| Consensus Rating | Upgrade |
| Target Price | |
| Price | 110.87 |
| Price Target | Upgrade |
| Price Target Upside (Daily) | Upgrade |
Top Fund Holders
| Symbol | Name | Weighting |
|---|---|---|
| CIG4924 | CI Global Health Sciences Corp Cl Y | 5.16% |
| FBT | First Trust NYSE Arca Biotech ETF | 4.82% |
| BBP | Virtus LifeSci Biotech Products ETF | 3.27% |
| XBI | SPDR® S&P Biotech ETF | 2.26% |
| VLLIX | Value Line Larger Companies Focus Instl | 2.17% |
| BFONX | Biondo Focus Investor | 1.80% |
| VLIIX | Value Line Capital Appreciation Instl | 1.65% |
| LAUCX | Columbia Acorn USA C | 1.29% |
| LABU | Direxion Daily S&P Biotech Bull 3X ETF | 1.20% |
| RYJ | Invesco Raymond James SB-1 Equity ETF | 0.87% |
| FIJYX | Fidelity Advisor® Biotechnology Z | 0.74% |
| ISMD | Inspire Small/Mid Cap Impact ETF | 0.31% |
Other Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- ICPT Tweets Stocktwits
Advertisement
